<DOC>
	<DOCNO>NCT00756223</DOCNO>
	<brief_summary>The main objective trial provide safety data term drug-related adverse event recommendation dose trial development BI 831266 . Secondary objective collection antitumour efficacy data determination pharmacokinetic pharmacodynamic profile BI 831266 .</brief_summary>
	<brief_title>Phase I Study BI 831266 Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Patients confirm diagnosis advance , nonresectable and/or metastatic solid malignant tumour , fail conventional treatment therapy proven efficacy exist amenable establish treatment option 2 . Secure central venous access 3 . Measurable and/or nonmeasurable tumour deposit 4 . Recovery toxicity prior anticancer therapy least CTCAE grade 1 5 . Age &gt; = 18 year 6 . Life expectancy &gt; = 3 month 7 . Written inform consent accordance International Conference Harmonisation guideline Good Clinical Practice local legislation 8 . Eastern Cooperative Oncology Group performance score &lt; = 2 Exclusion criterion : 1 . Serious illness , concomitant nononcological disease ( e.g . active infectious disease ) , ongoing toxicity prior therapy consider investigator potentially compromise patient ' safety trial 2 . Pregnancy breastfeed 3 . Symptomatic brain metastasis and/or leptomeningeal disease require therapy 4 . Second malignancy require therapy 5 . Left ventricular ejection fraction ( LVEF ) &lt; 50 % echocardiography 6 . Clinically significant ( i.e . active ) cardiovascular disease : CVA/stroke ( &lt; = 6 month prior randomisation ) , myocardial infarction ( &lt; = 6 month prior randomisation ) , unstable angina , New York Heart Association Grade II great congestive heart failure , serious cardiac arrhythmia require medication 7 . Absolute neutrophil count less 1500 / mm3 8 . Platelet count less 100 000 / mm3 9 . Bilirubin great 1.5 mg / dl ( &gt; 26 micromol / L , SI unit equivalent ) 10 . Aspartate amino transferase ( AST ) / alanine amino transferase ( ALT ) great 2.5 time upper limit normal ( related liver metastasis great five time upper limit normal ) 11 . Serum creatinine great 1.5 mg / dl ( &gt; 132 micromol / L , SI unit equivalent ) 12 . Women men sexually active unwilling use medically acceptable method contraception 13 . Treatment investigational drug another clinical trial within past two week start therapy concomitantly trial 14 . Chemo , hormone , radio immunotherapy within past two week start therapy concomitantly trial 15 . Patients unable comply protocol 16 . Active alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>